Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-shelf, Third-party Natural Killer Cells (KDS-1001) for the Induction of Relapsed/Refractory Acute Myeloid Leukemia

NCT04220684 is registered in ClinicalTrials.gov with Sumithira Vasu as lead sponsor.

NCT NCT04220684
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04220684 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-shelf, Third-party Natural Killer Cells (KDS-1001) for the Induction of Relapsed/Refractory Acute Myeloid Leukemia
Lead sponsor
Sumithira Vasu
Phase
Phase 1
Overall status
Completed
Start date
June 11, 2020
Completion date
October 22, 2024
Enrollment
19 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

allogeneic stem cell transplant recipient, blasts 10 percent or more of bone marrow nucleated cells, recurrent acute myeloid leukemia, refractory acute myeloid leukemia